TD Cowen analyst Marc Frahm reiterated a Buy rating on Cullinan Oncology Inc. (NASDAQ: CGEM).The analyst commented: "Full Speed Ahead ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE